Healthcare
Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
Company announcement No. 45 / 2026
Sep 2 · 15:00GlobeNewswire
6,990 press releases indexed under healthcare.
Company announcement No. 45 / 2026
Morgan Health, CVS Health Ventures, and Humana, alongside other strategic payers and providers, invest in Thyme Care at a valuation of more than $2B The new capital accelerates Thyme Care's continued growth and establishes Thyme Companies, a newly formed parent entity building a broader...
AMHERST, Mass., Sept. 2, 2026 /PRNewswire/ -- UMass Athletics and Baystate Health, in collaboration with Learfield's UMass Sports Properties, announced today an expanded, multi-year partnership that will bring new on-field branding and additional fan engagement opportunities to UMass...
ST. LOUIS, Sept. 2, 2026 /PRNewswire/ -- Home State Health is proud to recognize Dr. Daniel G. Rudolph and Dr. Joshua P. Boldt of Kidz Biz Pediatrics as recipients of the Clinical Quality Champion Award. The award honors physicians who demonstrate exceptional commitment to delivering...
MECHANICSBURG, Pa. and STERLING HEIGHTS, Mich., Sept. 2, 2026 /PRNewswire/ -- Select Medical Corporation and Corewell Health today announced a joint venture partnership to build and operate a new 84-bed inpatient rehabilitation hospital in Sterling Heights, Mich., next to Corewell Health...
Healthcare Policy Expert Augusta Uwah, MD, MPH Selected as Reviewer at Becker's Health IT + Digital Health + RCM Conference The post Dr Augusta Uwah, Selected as Reviewer at Becker's Health IT + Digital Health + RCM Conference first appeared on
(PR-inside.com) WASHINGTON, D.C. / ACCESS Newswire / September 2, 2026 / Hispanic and Latino patients are delaying treatment, rationing medication, taking on debt, and traveling abroad to purchase prescription drugs because they cannot afford the high prices charged in the United States, according to a new report released today by Patients For Affordable Drugs, We Are Más, and Brown University's Information Futures Lab. The Price Patients Pay: How Unaffordable Prescription Drugs Shape the Health, Finances, and Daily Lives of Hispanic and Latino Communities offers a look beyond national statistics and examines the experiences of patients navigating the U.S. prescription drug affordability crisis. ..
GREENWICH, Conn., September 02, 2026--Private Medical opens its seventh location in Greenwich, Connecticut, expanding concierge, prevention-first primary care to Fairfield County.
AUSTIN, Texas, Sept. 2, 2026 /PRNewswire/ -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first facility in the nation to participate in a clinical trial to evaluate the safety and effectiveness of a next-generation mapping and pulsed...
Center City, Minnesota--(Newsfile Corp. - September 2, 2026) - The nonprofit Hazelden Betty Ford Foundation, a national leader in substance use and mental health care, today released its annual patient outcomes report from the Butler Center for Research—finding that 70% of patients reported abstinence one year after treatment, 75% achieved recovery-capital levels associated with sustained recovery, and more than 85% reported good overall health and quality of life.The report reflects data from a...
Appointment strengthens board independence and financial expertise as Company advances its clinical pipeline.
This Strategic Engagement is Designed to Strengthen NeuroThera’s U.S. Market Position, Visibility Among Key U.S. Federal Stakeholders, Reinforce the Clinical and Public ‑H ealth Importance of Advancing New Treatment Options for Adult Tourette Syndrome TEL AVIV, ISRAEL - September 2, 2026 ( NEWMEDIAWIRE ) - SciSparc Ltd. (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced that it is pursuing U.S. Food and Drug Administration (“FDA”) Orphan Drug Designation covering SCI-110, its drug candidate for the treatment adults with Tourette Syndrome (“TS”), a rare condition that may qualify for Orphan Drug De